BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

380 related articles for article (PubMed ID: 32387695)

  • 21. Mechanisms of vaccine adjuvanticity at mucosal surfaces.
    Foss DL; Murtaugh MP
    Anim Health Res Rev; 2000 Jun; 1(1):3-24. PubMed ID: 11706842
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dendritic cell-targeting DNA-based nasal adjuvants for protective mucosal immunity to Streptococcus pneumoniae.
    Kataoka K; Fukuyama Y; Briles DE; Miyake T; Fujihashi K
    Microbiol Immunol; 2017 Jun; 61(6):195-205. PubMed ID: 28463465
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Subunit-based mucosal vaccine delivery systems for pulmonary delivery - Are they feasible?
    Marasini N; Kaminskas LM
    Drug Dev Ind Pharm; 2019 Jun; 45(6):882-894. PubMed ID: 30767591
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mucosal vaccines: a paradigm shift in the development of mucosal adjuvants and delivery vehicles.
    Srivastava A; Gowda DV; Madhunapantula SV; Shinde CG; Iyer M
    APMIS; 2015 Apr; 123(4):275-88. PubMed ID: 25630573
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Recent developments in adjuvants for vaccines against infectious diseases.
    O'Hagan DT; MacKichan ML; Singh M
    Biomol Eng; 2001 Oct; 18(3):69-85. PubMed ID: 11566599
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mucosal vaccines: recent progress in understanding the natural barriers.
    Borges O; Lebre F; Bento D; Borchard G; Junginger HE
    Pharm Res; 2010 Feb; 27(2):211-23. PubMed ID: 19953309
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inducing Mucosal IgA: A Challenge for Vaccine Adjuvants and Delivery Systems.
    Boyaka PN
    J Immunol; 2017 Jul; 199(1):9-16. PubMed ID: 28630108
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Chitosan-based Nanoparticles in Mucosal Vaccine Delivery.
    Mehrabi M; Montazeri H; Mohamadpour Dounighi N; Rashti A; Vakili-Ghartavol R
    Arch Razi Inst; 2018 Sep; 73(3):165-176. PubMed ID: 30280836
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Nanocarriers: a versatile approach for mucosal vaccine delivery.
    Mody N; Sharma R; Agrawal U; Vyas SP
    Ther Deliv; 2015 Feb; 6(2):231-45. PubMed ID: 25690089
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Advances and Potential Applications of Chitosan Nanoparticles as a Delivery Carrier for the Mucosal Immunity of Vaccine.
    Li D; Fu D; Kang H; Rong G; Jin Z; Wang X; Zhao K
    Curr Drug Deliv; 2017; 14(1):27-35. PubMed ID: 27494157
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Biocompatible Mater Constructed Microneedle Arrays as a Novel Vaccine Adjuvant- Delivery System for Cutaneous and Mucosal Vaccination.
    Wang T; Wang N
    Curr Pharm Des; 2015; 21(36):5245-55. PubMed ID: 26412356
    [TBL] [Abstract][Full Text] [Related]  

  • 32. New advances in mucosal vaccination.
    Ranasinghe C
    Immunol Lett; 2014 Oct; 161(2):204-6. PubMed ID: 24462961
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Jump-starting the immune system: prime-boosting comes of age.
    Woodland DL
    Trends Immunol; 2004 Feb; 25(2):98-104. PubMed ID: 15102369
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Recent advances in mucosal vaccine development.
    Chen H
    J Control Release; 2000 Jul; 67(2-3):117-28. PubMed ID: 10825547
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Surface modified nanoparticulate carrier constructs for oral mucosal vaccine delivery.
    Mishra N; Singh D; Sharma S; Baldi A
    Curr Drug Deliv; 2014; 11(6):729-43. PubMed ID: 25007830
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Archaeal lipid mucosal vaccine adjuvant and delivery system.
    Patel GB; Chen W
    Expert Rev Vaccines; 2010 Apr; 9(4):431-40. PubMed ID: 20370552
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bioadhesive delivery systems for mucosal vaccine delivery.
    Baudner BC; O'Hagan DT
    J Drug Target; 2010 Dec; 18(10):752-70. PubMed ID: 21039314
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mucosal Vaccine Development Based on Liposome Technology.
    Bernasconi V; Norling K; Bally M; Höök F; Lycke NY
    J Immunol Res; 2016; 2016():5482087. PubMed ID: 28127567
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mucosal immunity: overcoming the barrier for induction of proximal responses.
    McKenzie BS; Brady JL; Lew AM
    Immunol Res; 2004; 30(1):35-71. PubMed ID: 15258310
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Generation of improved mucosal vaccines by induction of innate immunity.
    Lavelle EC
    Cell Mol Life Sci; 2005 Dec; 62(23):2750-70. PubMed ID: 16237500
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.